RS62030B1 - Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci - Google Patents

Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci

Info

Publication number
RS62030B1
RS62030B1 RS20210674A RSP20210674A RS62030B1 RS 62030 B1 RS62030 B1 RS 62030B1 RS 20210674 A RS20210674 A RS 20210674A RS P20210674 A RSP20210674 A RS P20210674A RS 62030 B1 RS62030 B1 RS 62030B1
Authority
RS
Serbia
Prior art keywords
rep
chelate
antiviral
interferon
pegylated
Prior art date
Application number
RS20210674A
Other languages
English (en)
Serbian (sr)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of RS62030B1 publication Critical patent/RS62030B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
RS20210674A 2012-05-18 2013-05-17 Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci RS62030B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
EP13791618.5A EP2849798B1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
RS62030B1 true RS62030B1 (sr) 2021-07-30

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210674A RS62030B1 (sr) 2012-05-18 2013-05-17 Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci

Country Status (34)

Country Link
US (1) US9492506B2 (OSRAM)
EP (1) EP2849798B1 (OSRAM)
JP (1) JP2015517504A (OSRAM)
KR (1) KR102068109B1 (OSRAM)
CN (1) CN104349793B (OSRAM)
AU (1) AU2013262416B2 (OSRAM)
BR (1) BR112014028654A2 (OSRAM)
CA (1) CA2873529C (OSRAM)
CL (1) CL2014003134A1 (OSRAM)
CO (1) CO7131387A2 (OSRAM)
CR (1) CR20140527A (OSRAM)
CY (1) CY1124345T1 (OSRAM)
DK (1) DK2849798T3 (OSRAM)
DO (1) DOP2014000264A (OSRAM)
EA (1) EA035967B1 (OSRAM)
EC (1) ECSP14027694A (OSRAM)
ES (1) ES2873844T3 (OSRAM)
HR (1) HRP20210840T1 (OSRAM)
HU (1) HUE054875T2 (OSRAM)
IL (1) IL235548B (OSRAM)
LT (1) LT2849798T (OSRAM)
MX (1) MX346239B (OSRAM)
MY (1) MY168778A (OSRAM)
NZ (1) NZ703095A (OSRAM)
PH (1) PH12014502551B1 (OSRAM)
PL (1) PL2849798T3 (OSRAM)
PT (1) PT2849798T (OSRAM)
RS (1) RS62030B1 (OSRAM)
SG (1) SG11201407599SA (OSRAM)
SI (1) SI2849798T1 (OSRAM)
SM (1) SMT202100319T1 (OSRAM)
TW (1) TWI635864B (OSRAM)
WO (1) WO2013170386A1 (OSRAM)
ZA (1) ZA201408674B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
PT3166615T (pt) * 2014-07-10 2023-11-13 Replicor Inc Polímeros de ácidos nucleicos fosforotioados quelados para utilização em combinação com um inibidor da polimerase de hbv para o tratamento de infeções pelo vírus da hepatite b e hepatite d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010138806A2 (en) * 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8598334B2 (en) * 2009-10-16 2013-12-03 Glaxo Group Limited HBV antisense inhibitors
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
TWI635864B (zh) 2018-09-21
KR20150013309A (ko) 2015-02-04
CA2873529C (en) 2020-08-18
HUE054875T2 (hu) 2021-10-28
ECSP14027694A (es) 2015-12-31
DK2849798T3 (da) 2021-05-31
JP2015517504A (ja) 2015-06-22
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
AU2013262416B2 (en) 2017-05-11
EP2849798A4 (en) 2016-03-09
CN104349793A (zh) 2015-02-11
EP2849798A1 (en) 2015-03-25
WO2013170386A1 (en) 2013-11-21
CN104349793B (zh) 2017-11-10
CL2014003134A1 (es) 2015-02-13
EA201401278A1 (ru) 2015-04-30
LT2849798T (lt) 2021-08-10
AU2013262416A1 (en) 2014-12-18
US9492506B2 (en) 2016-11-15
CY1124345T1 (el) 2022-07-22
ES2873844T3 (es) 2021-11-04
SG11201407599SA (en) 2014-12-30
HK1204279A1 (en) 2015-11-13
HRP20210840T1 (hr) 2021-08-06
MY168778A (en) 2018-12-04
CO7131387A2 (es) 2014-12-01
ZA201408674B (en) 2016-01-27
MX2014014021A (es) 2015-02-10
SI2849798T1 (sl) 2021-08-31
DOP2014000264A (es) 2015-01-31
PT2849798T (pt) 2021-05-18
CR20140527A (es) 2014-12-15
CA2873529A1 (en) 2013-11-21
PH12014502551B1 (en) 2019-10-11
US20130309201A1 (en) 2013-11-21
MX346239B (es) 2017-03-13
EP2849798B1 (en) 2021-04-07
NZ703095A (en) 2016-07-29
EA035967B1 (ru) 2020-09-07
PH12014502551A1 (en) 2015-01-21
IL235548B (en) 2019-07-31
KR102068109B1 (ko) 2020-01-21
TW201408308A (zh) 2014-03-01
PL2849798T3 (pl) 2021-10-18
SMT202100319T1 (it) 2021-09-14

Similar Documents

Publication Publication Date Title
US20230210887A1 (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
RS62030B1 (sr) Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
US20190062749A1 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
TWI881004B (zh) 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合
CN113171371B (zh) 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用
WO2012021985A1 (en) Oligonucleotide chelate complexes
RS59914B1 (sr) Metode sa oligonukleotidnim helatnim kompleksom
CN116367841A (zh) 用于治疗病毒性疾病的含有核苷的siRNA
KR20240101580A (ko) Hbv 치료를 위한 약학 조합물
JP2023509872A (ja) Ｈｂｖを標的とする抗ウイルス剤及び／又はｈｂｖの処置のための免疫調節剤の医薬組合せ
HK1204279B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
RU2780021C2 (ru) Способы лечения инфекции гепатита в
WO2025087290A1 (zh) 一种药物组合物及其用途
CN119662639A (zh) 抑制乙型肝炎病毒基因表达的siRNA、其缀合物和药物组合物及用途
CN114767704A (zh) 一种能够靶向乙型肝炎病毒的药物构造及药物组合物
HK40032229B (zh) 治疗乙型肝炎感染的方法
HK40032229A (en) Methods for treating hepatitis b infection
HK40004694B (zh) 用於减少papd5或papd7 mrna治疗乙型肝炎感染的核酸分子
HK40004694A (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection